現実世界のために構築された EVプラットフォーム。

Most exosome products cannot tell you what is in the vial. We can. BioThera isolates plant-derived extracellular vesicles at manufacturing scale, counts them by Nanoparticle Tracking Analysis, and characterizes every batch against MISEV2023 — the consensus standard our founder helped write. One platform, one Certificate of Analysis, many applications.

細胞外小胞(EV/エクソソーム)

このナノスケール送達システムに含まれる生理活性分子を示すリアルタイム構造モデル

Phospholipid bilayerSurface proteinsBiomolecular coronaIntraluminal cargoRNA molecules

BioThera Solutionsは何をしていますか?

BioThera Solutions operates across three integrated layers: plant-derived EV isolation and MISEV2023-compliant biomanufacturing, rigorous particle characterization, and formulation into finished applications. The same workflow supplies every application built on the platform, and every batch leaves with the Certificate of Analysis behind it.

EV Biomanufacturing

Scalable. Standardized. Reproducible.

Proprietary isolation and scale-up engineered for consistency — batch-level characterization, cold-chain integrity, and standardized quality control across plant-derived EV modalities.

Characterization & Standards

MISEV2023, by a named contributor.

Every batch is counted by Nanoparticle Tracking Analysis, screened for contaminants, and characterized against the MISEV2023 marker framework. The number on the Certificate of Analysis is a measured number, not an estimate.

Applications

One platform, several end markets.

The same workflow supplies skincare and dermocosmetics today, and is being evaluated against clinical dermatology, wound and barrier repair, regenerative medicine, and drug delivery. One isolation and characterization process behind all of them.

One process. Several end markets.

BioThera isolates plant-derived extracellular vesicles, characterizes them against MISEV2023, and documents every batch. Formulation is downstream of that. The areas below are where the platform applies, each with an honest note on how far it has actually gone.

  • Skincare & dermocosmetics: supplied exclusively to Vesera™, a dermocosmetic brand
  • Clinical dermatology: in evaluation
  • Wound & barrier repair: research direction
  • Regenerative medicine: research direction
  • Drug delivery: research direction
カナダで製造
MISEV2023に基づく特性評価
Leaping Bunny認証
独自技術 — IP保護進行中
皮膚科医との積極的な安全性・有効性研究
カナダで製造
MISEV2023に基づく特性評価
Leaping Bunny認証
独自技術 — IP保護進行中
皮膚科医との積極的な安全性・有効性研究

Building on plant-derived exosomes? Start a conversation.

We work with research, clinical and industry partners. Whether you are exploring co-development, licensing or a research collaboration, reach out.

BioThera Solutions

ダーモコスメティックおよびEVベースのスキンケア用途のためのスケーラブルなEVバイオ製造。細胞外小胞(EV/エクソソーム)は、信頼できる科学主導のスキンケアのあり方を再定義しつつあります — 私たちはそのインフラをゼロから構築しています。

Ottawa, Ontario, Canada
カナダ、オンタリオ州 オタワ

© 2026 BioThera Solutions Inc. 全著作権所有。

For informational purposes only. BioThera manufactures characterized plant-derived extracellular vesicles (exosomes) and supplies its highest-grade material exclusively to Vesera™, a dermocosmetic brand. Vesera™ products are cosmetics and are not intended to diagnose, treat, cure, or prevent any disease. BioThera material is supplied for research and cosmetic manufacturing use and has no approved therapeutic indication.